Stryker Corporation is a medical technology company operating in the United States and internationally. It has two segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication and AI-assisted virtual care platform technology, and minimally invasive products for acute ischemic and hemorrhagic stroke and venous thromboembolism, as well as traditional brain and open skull based surgical products and orthobiologic and biosurgery products. The Orthopaedics segment provides implants for total joint replacements (hip, knee, shoulder, ankle) and trauma and extremities surgeries, and Mako Shoulder, which expands the smart robotics suite. The company sells to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, and third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope
▼
Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
▼
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
▲
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
▲
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.
Latest
▲3▼1
Stryker's strong demand and new tech offset by supply and joint replacement setbacks
▲
Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.
This is the fundamental earnings result that anchors the period's positive momentum.
▲
$100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.
A concrete new contract that adds demand and supports the stock.
▲
Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.
Highlights innovation and strategic growth that drive future revenue and market share.
▼
Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.
This is the major negative event that caused a sharp sell-off and reflects real operational challenges.
Q3 2026
▲3▼1
Stryker's strong Q2 beat offset by supply snag and joint replacement weakness
▲
Q2 beat and raised guidance Stryker's Q2 sales rose 9.4% to $6.6B and adjusted EPS hit $3.69, beating expectations, prompting management to raise full-year guidance. This shows the core business is healthy and growing faster than expected.
This is the main positive fundamental driver for the period, showing strong financial performance.
▲
Mako robotics milestone and new product launch Mako robotics surpassed 2.5 million procedures, and Stryker launched the Mako RPS handheld knee system. These innovations strengthen Stryker's position in the growing healthcare robotics market and support future demand.
Highlights technological leadership and new product momentum, key for long-term growth.
▲
$100M defense contract and tech partnerships Stryker won a $100M defense contract and advanced acquisitions and Apple Vision Pro technology. This government validation and tech integration open new revenue streams and enhance Stryker's product offerings.
Shows diversification and external validation, which can boost investor confidence.
▼
Manufacturing issue and joint replacement weakness A manufacturing problem limiting inventory and new business is expected to persist into Q4, and joint replacement underperformed on seasonal patterns. These headwinds dragged shares down 7.7% and left SYK down 6.5% YTD.
This is the main negative force that offset strong fundamentals and pressured the stock price.
News & notes movingSYK
GlobalUnited States
Robotics & Physical AI▲
Medical Robots Market Projected to Reach $41.7 Billion by 2031
The global medical robots market is projected to grow from USD 20.6 billion in 2026 to USD 41.7 billion by 2031, a 15.1% compound annual growth rate, according to a new report added to ResearchAndMarkets.com. Robotic systems are expected to account for the largest share of the market by product and service, while surgical robotic systems, which led by type in 2025, are expected to see significant growth as surgical volumes rise. Ambulatory surgery centers are projected to register the highest end-user growth rate, and Asia Pacific is positioned as the fastest-growing regional market. Key players profiled include Intuitive Surgical, Stryker, Medtronic, and Johnson & Johnson. The report notes that high system and maintenance costs, stringent regulatory requirements, and specialized training needs may limit adoption.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
ISRG · Demand · Positive Named as a key player in the medical robots market projected to grow at 15.1% CAGR, with surgical robotic systems leading by type as surgical volumes rise.
JNJ · Demand · Positive Profiled as a key player in the growing medical robots market, though no company-specific development is cited.
MDT · Demand · Positive Listed among key players in the medical robots market expected to reach $41.7B by 2031.
SYK · Demand · Positive Named as a key player in the expanding medical robots market, with no company-specific news.
Stryker Faces Cybersecurity Costs and Peripheral Vascular Supply Drag as Mako Robotics and 9% Organic Growth Support 2026 Outlook
Stryker is holding up under a Zacks Rank #3 (Hold) rating as the medical technology company works through the financial fallout of a cybersecurity incident that disrupted manufacturing and continues to weigh on 2026 results. The company posted 9% organic sales growth in the second quarter of 2026, with MedSurg & Neurotechnology up 9.2% and Orthopaedics up 8.6%, while international sales rose 8.9% on strength in Australia, Germany, Canada, India and Brazil. Adjusted earnings per share climbed 17.9% to $3.69, adjusted gross margin expanded 60 basis points to 66% and adjusted operating margin rose 170 basis points to 27.4%, supporting management's full-year adjusted EPS outlook of $14.95 to $15.10. Mako robotics remains a central growth driver, with more than 2.5 million procedures completed globally and systems installed across 47 countries, and the full commercial launch of Mako Shoulder and Mako RPS broadens the platform's procedure base. Offsetting those gains, a supply disruption at a facility supporting the Inari portfolio has left Peripheral Vascular with a significant backlog and lost second-quarter sales that management estimates could represent roughly 50 to 75 basis points of organic growth drag, with backorders expected to reach manageable levels by the end of the third quarter. Stryker shares have lost 21.7% so far this year, roughly in line with the industry's 21.6% decline, while the S&P 500 Index has appreciated 13.2% over the same period, and the company carries a market capitalization of $105.7 billion.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
SYK · Capital · Neutral Q2 2026 results: 9% organic growth, adjusted EPS up 17.9% to $3.69, margins expanded, FY EPS outlook $14.95-$15.10
SYK · Regulation · Negative Cybersecurity incident disrupted manufacturing and its financial fallout continues to weigh on 2026 results
SYK · Supply · Negative Supply disruption at an Inari-supporting facility left Peripheral Vascular with a backlog and lost Q2 sales, ~50-75 bps organic growth drag
Stryker Launches Prophecy Surgical Planning for Incompass and Hoffmann LRF smartHEX at AOFAS 2026
Stryker announced at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle that it is launching Prophecy Surgical Planning for the Incompass Total Ankle System and introducing Hoffmann LRF smartHEX. Prophecy Surgical Planning, which has supported patient-specific planning for more than 100,000 ankle cases over 14 years, is now available with the Incompass Total Ankle System, giving surgeons access to 3D visualization and both resect-through and pin-through fixation options within a single connected platform. The Incompass Total Ankle System was created using insights generated through Prophecy and SOMA, Stryker Orthopaedic Modeling and Analytics, incorporating real-world anatomy and surgical planning into the implant design. Hoffmann LRF smartHEX expands Stryker's limb reconstruction portfolio with new rings, struts and frame components along with a mobile app and reimagined planning software designed to enhance frame versatility and support connected care. Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business, said bringing Prophecy to Incompass combines patient-specific planning with the company's newest total ankle system, helping surgeons make more informed decisions before they enter the operating room. Attendees can experience both technologies and Stryker's full Foot & Ankle portfolio at AOFAS 2026, booth #601.
SYK · Technology · Positive Stryker launched Prophecy Surgical Planning for the Incompass Total Ankle System and introduced Hoffmann LRF smartHEX, expanding its Foot & Ankle product portfolio.
Stryker shares tumble 7.7% on supply chain and joint replacement woes
Stryker Corp. shares dropped as much as 7.7% on Tuesday after executives discussed ongoing problems in its peripheral vascular and joint replacement operations at the Wells Fargo Healthcare Conference. Chief Financial Officer Preston Wells said a manufacturing problem continues to limit inventory supply and new business opportunities, with the issue now expected to persist into the fourth quarter. The joint replacement business also underperformed due to more typical seasonal patterns, though the company anticipates a better September. Shares of peer Zimmer Biomet also declined.
Global Surgical Robots Market to Reach $22.9 Billion by 2035
A new report from ResearchAndMarkets.com projects the global surgical robots market will grow from USD 10.6 billion in 2026 to USD 22.9 billion by 2035, a compound annual growth rate of about 8.9%. The expansion is driven by demand for minimally invasive surgery, AI integration, and compact systems that lower capital costs. North America is expected to lead the market, while Asia-Pacific is forecast to see the fastest growth. Key players include Intuitive Surgical, Medtronic, Johnson & Johnson, and Stryker. Recent developments include Medtronic's FDA clearance for its Hugo system in urology and a partnership between Ronovo Surgical and Johnson & Johnson Medical Shanghai.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
MDT · Regulation · Positive Received FDA clearance for its Hugo surgical robot system in urology, a concrete regulatory milestone in this market.
ISRG · Demand · Positive Named as a key player in a surgical robots market projected to nearly double by 2035 on minimally invasive surgery demand.
Ronovo Surgical (Shanghai) Medical Science & Technology Ltd. · Demand · Positive Formed a partnership with Johnson & Johnson Medical Shanghai in the surgical robotics space.
JNJ · Demand · Positive Named as a key player and its J&J Medical Shanghai unit partnered with Ronovo Surgical in the growing surgical robotics market.
SYK · Demand · Positive Named as a key player in the surgical robots market forecast to grow to $22.9 billion by 2035.
Stryker Completes First Hip Arthroscopy with FDA-Cleared Apple Vision Pro App
Stryker announced the successful completion of the first hip arthroscopy procedure using its SportSuite Vision application on Apple Vision Pro at Duke Health, following the FDA's De Novo authorization in July, making it the first surgical application approved for intraoperative use with Apple's mixed reality headset. The procedure was performed by orthopedic surgeon Chad Mather III, demonstrating the platform's transition from regulatory clearance to real-world clinical adoption. SportSuite Vision is designed for femoroacetabular impingement and labral repair procedures, combining arthroscopic video, HipCheck, HipMap FAI Analysis, and CT imaging in a customizable spatial computing environment. While the launch is unlikely to materially affect near-term revenue, it could enhance Stryker's competitive position and support long-term growth as hospitals adopt advanced operating room technologies. Shares of Stryker traded flat on Wednesday, and year to date, the stock has lost 11.1% compared with the industry's 17% decline, while the S&P 500 has risen 10.9%. Stryker also recently agreed to acquire ZuriMED, developer of the FiberLocker System for rotator cuff augmentation, to strengthen its shoulder portfolio.
SYK · Technology · Positive First hip arthroscopy performed using Stryker's FDA-cleared SportSuite Vision app on Apple Vision Pro, marking real-world clinical adoption of its new surgical platform.
SYK · Capital · Positive Stryker agreed to acquire ZuriMED, developer of the FiberLocker System, to strengthen its shoulder portfolio.
Stryker to Acquire ZuriMED for Rotator Cuff Technology
Stryker has signed a definitive agreement to acquire ZuriMED, the developer of the FiberLocker System, a commercialized technology for rotator cuff augmentation designed to increase biomechanical strength. The acquisition strengthens Stryker's shoulder portfolio, enhancing its support for specialists across sports medicine and arthroplasty. Rotator cuff augmentation is one of the fastest-growing segments in sports medicine, and the FiberLocker System addresses a key clinical failure mode in rotator cuff repair. The transaction is subject to customary closing conditions, and both companies will operate separately until then.
Stryker's Strong Demand and Robotics Growth Offset Cyber Disruption
Stryker delivered 9% organic sales growth in the second quarter of 2026, with adjusted EPS rising 17.9% to $3.69, despite ongoing impacts from a cybersecurity incident and a Peripheral Vascular supply disruption. MedSurg & Neurotechnology grew 9.2% and Orthopaedics grew 8.6%, while international sales rose 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako robotics surpassed 2.5 million procedures globally across 47 countries, with U.S. knee sales up 6.2% and Ortho Tech up 9.2% on robust installations. Management maintained full-year EPS guidance of $14.95-$15.10, though the Peripheral Vascular disruption is expected to drag organic growth by roughly 50-75 basis points until backorders normalize by the end of the third quarter. The Zacks Consensus Estimate for 2026 earnings has risen 3 cents to $15.02 per share over the past 60 days.
Stryker Wins $100 Million Defense Logistics Agency Contract
Stryker's Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. The contract news pushed Stryker higher, with the stock last closing at $327.70. The most followed narrative on Stryker currently points to a fair value of $386.80 per share, suggesting the stock is 15.3% undervalued. That valuation rests on a detailed view of procedure demand, margins, and how the business responds to hospital digitization over time. However, the narrative still relies on smooth regulatory approvals and stable procedure volumes, and setbacks in either could quickly challenge today's pricing optimism.
Stryker's Growth Improves but Execution Risks Persist
Stryker Corporation delivered 9% organic sales growth in the second quarter of 2026, with adjusted earnings up 17.9% to $3.69 per share and adjusted operating margin rising 170 basis points to 27.4%. MedSurg and Neurotechnology grew 9.2% organically while Orthopaedics increased 8.6%, and management narrowed its full-year organic sales growth outlook to 8.3% to 9.3%. The stock trades at 20.4 times forward earnings, below its five-year median of 26.0 times but above the Zacks sub-industry average of 16.9 times. Stryker ended the quarter with about $3.5 billion in cash and marketable securities, operating cash flow of $1.8 billion in the first half, and long-term debt down to $14.2 billion from $14.9 billion at year-end 2025. The company plans to resume share repurchases in the second half, while cyber remediation costs, vascular supply constraints, and acquisition integration keep execution risk elevated.
Stryker shares drop 6.4% after Q2 earnings, trading at 23% discount to fair value estimate
Stryker shares fell 6.42% following its second quarter 2026 earnings release, which reported sales of US$6.59 billion and net income of US$1.28 billion. The decline pulled the year-to-date return down 6.46%, though the five-year total shareholder return remains at 30.66%. After the drop, Stryker is trading at a discount of about 23% to one valuation estimate and roughly 18% below the average analyst target, with the most followed narrative placing fair value at $386.80 versus the last close of $325.70. Analyst price targets range from a bullish $465.00 to a bearish $315.00, with a consensus of $386.80. The narrative highlights compounding revenue, rising margins, and a richer earnings multiple, but notes risks from prolonged EU regulatory delays or sustained supply chain disruptions.
Stryker Corporation reported second-quarter 2026 sales of US$6,589 million and net income of US$1,276 million, with both basic and diluted EPS from continuing operations rising year-over-year. Management highlighted 9% organic sales growth, progress in recovering from a March cyberattack that disrupted operations, and a slight increase to full-year adjusted EPS guidance while planning to resume share repurchases. The company also announced the US commercial launch of the Mako RPS robotic power system for total knee replacement, alongside record Mako installations during the quarter. Persistent supply chain disruptions and backorders remain a risk, though the results suggest progress without a complete resolution.
Stryker reported second-quarter adjusted earnings of $3.69 per share, beating the Zacks Consensus Estimate of $3.46 per share and marking a 6.65% earnings surprise. Revenue came in at $6.59 billion, surpassing the consensus estimate by 0.48% and up from $6.02 billion a year ago. The company has topped consensus EPS estimates three times in the past four quarters. Stryker shares have added about 0.2% year to date, underperforming the S&P 500's 6.9% gain. The current Zacks Rank for the stock is #3 (Hold), with consensus estimates for the coming quarter at $3.73 per share on $6.72 billion in revenues.
DCLA’s Sarat Sethi says Alphabet has many levers to toggle on AI spending
DCLA managing partner Sarat Sethi expressed concern about massive AI capital expenditure plans at tech companies outside of Alphabet, while calling Alphabet a core portfolio holding because its diversified businesses give it many levers to toggle. He pointed to YouTube, Cloud, and Gemini as reasons Alphabet can adjust spending if returns on investment do not materialize. Sethi noted a divergence between hardware and software spending, with customers holding back on hardware while continuing to invest in software and security, citing IBM and SAP commentary. He said Microsoft faces particular scrutiny and must show return on investment faster than others, as the stock is already down double digits this year. Beyond tech, Sethi highlighted a rotation into high-quality, cash-flow-generating healthcare companies such as Stryker, Thermo Fisher, and Johnson & Johnson, noting the healthcare sector has shrunk to its smallest S&P 500 weighting ever.
Artificial Intelligence › AI Server OEM & System Integration ▼Demand
Cloud & Digital Infrastructure › Mega-cap Hyperscalers ▼Capital
Artificial Intelligence › AI Data Center & Build-out ▼Capital
Artificial Intelligence › AI Compute Cloud & Neoclouds ▼Capital
GOOG · Capital · Positive Sethi calls Alphabet a core holding with diversified businesses (YouTube, Cloud, Gemini) that give it levers to adjust AI spending if returns don't materialize, implying lower risk.
MSFT · Capital · Negative Sethi says Microsoft faces particular scrutiny and must show ROI faster than others, with stock already down double digits this year.
SYK · Demand · Positive Sethi highlights rotation into high-quality healthcare companies like Stryker, implying increased investor demand.
IBM · Demand · Neutral Mentioned as example of customers holding back on hardware but continuing software/security spending; not a central focus.
JNJ · Demand · Positive Article notes rotation into high-quality healthcare companies like Johnson & Johnson, implying increased investor demand.
SAP.XETRA · Demand · Neutral Mentioned as example of customers continuing software/security spending; not a central focus.
Robotic Endoscopy Devices Market to Reach $6.5 Billion by 2034
The global robotic endoscopy devices market is projected to grow from $2.8 billion in 2025 to $6.5 billion by 2034, at a compound annual growth rate of approximately 10%, according to a report by DelveInsight. North America accounted for about 42% of global revenue in 2025, driven by widespread adoption of robotic-assisted surgical technologies and the presence of major players such as Intuitive Surgical, Medtronic, and Johnson & Johnson MedTech. The therapeutic robotic endoscopes category was the largest product segment, while the Asia-Pacific region is expected to see the highest growth due to aging populations and rising investments in robotic surgery. Key companies in the market include Intuitive Surgical, Johnson & Johnson MedTech, Medtronic, Olympus, Boston Scientific, FUJIFILM, Stryker, KARL STORZ, Asensus Surgical, and CMR Surgical. Recent developments include FDA clearance of Medtronic's Hugo system for urologic procedures in December 2025 and FDA 510(k) clearance of CMR Surgical's Versius Plus system for cholecystectomy.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
ISRG · Demand · Positive Market growth forecast and Intuitive Surgical's leading position in robotic endoscopy drive positive demand outlook.
CMR Surgical · Regulation · Positive FDA 510(k) clearance of CMR Surgical's Versius Plus system for cholecystectomy is a regulatory approval that enables market expansion.
MDT · Technology · Positive FDA clearance of Medtronic's Hugo system for urologic procedures is a positive regulatory milestone.
JNJ · Demand · Positive Johnson & Johnson MedTech is a major player in the growing robotic endoscopy market.
BSX · Demand · Positive Boston Scientific is a key company in the expanding robotic endoscopy market.
SYK · Demand · Positive Stryker is listed as a key player in the growing robotic endoscopy devices market.
Source Logistics warns supply chain industry about rising data-wiping cyberattacks
Source Logistics is warning the supply chain industry about a growing threat of data-wiping cyberattacks that destroy systems and backups rather than demand ransom. The alert follows a March 2026 breach at medical technology company Stryker, where attackers used Microsoft Intune to remotely wipe an estimated 80,000 devices over roughly three hours after gaining Global Administrator-level access. Security researchers at Outpost24 identified 278 compromised credentials tied to the stryker.com domain between October 2025 and March 2026, including 83 in the weeks before the attack, highlighting how stolen credentials enable such destructive intrusions. Source Logistics' defense strategy focuses on phishing-awareness training and limiting administrative privileges, since data-wiping attacks typically require elevated access. The company also undergoes annual third-party cybersecurity audits and is working toward a NIST-aligned security framework, leveraging its SaaS-first, API-first technology platform to adapt security posture more quickly than legacy systems.
SYK · Technology · Negative Stryker suffered a March 2026 breach where attackers wiped 80,000 devices via Microsoft Intune, with 278 compromised credentials found.
Source Logistics · Demand · Positive Source Logistics warns about rising data-wiping attacks and promotes its cybersecurity services, positioning itself as a solution provider.
Outpost24 · Technology · Neutral Outpost24 identified compromised credentials related to the Stryker breach, but the article does not indicate impact on Outpost24 itself.
CONMED to Present AirSeal Trial Data at Robotic Surgery Meeting
CONMED Corporation announced its participation in the Society of Robotic Surgery 2026 Annual Meeting, where Professor Nikhil Vasdev will present results from a clinical trial comparing CONMED's AirSeal Insufflation System to Stryker's PneumoClear Insufflator. The prospective randomized controlled trial of 40 patients undergoing robotic prostatectomy found that the AirSeal arm had fewer significant nociceptive events per recorded hour, 20.7 versus 33.5, with a p-value of 0.041. Shorter procedure times, console times, and less blood loss were also observed in the AirSeal arm. The results were published in JUI Compass in May 2026. CONMED will also host a session on low-pressure insufflation in robotic surgery featuring several surgeons.
Stryker Launches Mako RPS Handheld Robotic Knee System in the U.S.
Stryker announced the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacement, on 16 July 2026. The system combines intraoperative planning with a robotically enabled saw and integrates with the Triathlon Total Knee System and Q Guidance platform. This launch extends the Mako ecosystem beyond robotic-arm systems into handheld robotics, potentially broadening adoption by matching robotic precision with familiar surgical workflows. The move reinforces Stryker's robotics catalyst but does not materially change near-term sensitivities around supply chain reliability and pricing pressures ahead of upcoming earnings.
Surgical Robots Market to Reach USD 27.14 Billion by 2030, Growing at 14.7% CAGR
The global surgical robots market is projected to grow from USD 13.69 billion in 2025 to USD 27.14 billion by 2030, at a compound annual growth rate of 14.7%, according to a new report by MarketsandMarkets. Growth is driven by increasing demand for minimally invasive surgeries, rising surgical volumes linked to chronic diseases and an aging population, and advances in robotic platforms, 3D visualization, AI-assisted navigation, and surgical instrumentation. Instruments and accessories represent the largest offering segment, general surgery is the largest application segment, and hospitals and clinics are the largest end-user segment. Asia Pacific is expected to be the fastest-growing regional market, with key players including Intuitive Surgical, Stryker Corporation, Medtronic, Smith+Nephew, and Zimmer Biomet.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
Aging Population › Medical Devices for the Aging Body ▲Demand
ISRG · Demand · Positive Market growth forecast driven by rising demand for minimally invasive surgeries and robotic platforms, directly benefiting Intuitive Surgical as a key player.
MDT · Demand · Positive Market growth forecast includes Medtronic as a key player, indicating increased demand for its surgical robotics offerings.
SYK · Demand · Positive Market growth forecast includes Stryker as a key player, implying rising demand for its surgical robots.
SN.LSE · Demand · Positive Market growth forecast includes Smith+Nephew as a key player, indicating favorable demand trends for its surgical robotics.
ZBH · Demand · Positive Market growth forecast includes Zimmer Biomet as a key player, suggesting increased demand for its surgical robotics products.
Bell Global Equities Fund Adds Stryker as New Position in May 2026
Bell Global Equities Fund initiated a new position in Stryker Corporation during May 2026, citing the medical technology company's quality characteristics and an attractive entry point after a share-price decline. The fund highlighted Stryker's best-in-class management, decentralized operating model delivering organic revenue growth ahead of large-cap medtech peers, and durable competitive advantages anchored by the Mako robotics platform. The opportunity arose from a broader medtech de-rating and stock-specific weakness following a March cyberattack that temporarily disrupted operations, with shares falling to 52-week lows after the first-quarter result quantified the impact. Bell Global Equities Fund views the disruption as transitory, noting that underlying procedure volumes held steady, the order book remains elevated, and management maintained full-year organic sales growth guidance of 8 to 9.5 percent, with most delayed sales expected to be recouped over the remainder of 2026. The forward price-to-earnings multiple compressed to approximately 19 times from the 25 to 30 times range a year earlier, which the fund saw as a meaningful discount to history and relative to Stryker's quality and growth characteristics.
Healthcare Automation Emerges as Next Growth Driver for Robotics ETFs
Healthcare robotics has reached mainstream scale, driven by an aging population, clinician shortages, and demand for minimally invasive procedures. Intuitive Surgical grew its da Vinci installed base 12% to 11,395 systems as of March 31, 2026, with procedures up about 16% year over year in the first quarter. Illumina and Stryker also exemplify the trend through lab automation and the Mako orthopedic system, respectively. The global healthcare robotics market is projected to rise from approximately $14.9 billion in 2023 to $57.0 billion by 2032, according to Johns Hopkins University. Among robotics ETFs, the Global X Robotics & Artificial Intelligence ETF holds Intuitive Surgical as its fifth position at 6.72% weight, the ROBO Global Robotics and Automation Index ETF holds Intuitive Surgical fourth at 1.77% and Illumina sixth at 1.69%, and the First Trust NASDAQ Artificial Intelligence and Robotics ETF holds Illumina fourth at 1.75%.
BTIG Reiterates Buy Rating on Stryker with $379 Price Target
BTIG analyst Ryan Zimmerman reiterated a Buy rating and a $379 price target on Stryker Corp. on June 12. The bullish stance is driven by the company's Mako robotic system, which has become a leading platform for ambulatory surgery centers. Stryker is increasingly capitalizing on robotics in healthcare as young surgeons treat robotic systems as a baseline requirement and patients actively seek robotic-assisted procedures. The company's flexible contract structures, including volume-based agreements and walk-away clauses, are fueling robotics adoption by lowering financial risk barriers. Earlier, on May 26, Stryker launched its Pangea Plating System in Europe to treat a wide range of fracture patterns.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
SYK · Technology · Positive BTIG reiterates Buy rating citing Stryker's Mako robotic system as a leading platform driving adoption, and the launch of Pangea Plating System in Europe.
Stryker praised for cash flow, Baker Hughes and Core Laboratories flagged as risky
StockStory highlights Stryker as a cash-producing stock worth watching, while flagging Baker Hughes and Core Laboratories as facing challenges. Stryker's trailing 12-month free cash flow margin stands at 18.1%, with organic revenue growth averaging 9.2% over the past two years and EPS compounding at 12.2% annually over five years. Baker Hughes, with a free cash flow margin of 8.9%, has seen annual sales growth of 6.8% over five years and a gross margin of 22.1% that trails competitors. Core Laboratories, at a 3.5% free cash flow margin, posted muted 3.4% annual revenue growth over five years and a gross margin of 20.4%.
Stryker Corporation will release its second quarter 2026 financial results on July 30, 2026, followed by a webcast to discuss the results. In the first quarter of 2026, net sales increased 2.6% to $6.02 billion, driven by MedSurg and Neurotechnology net sales of $3.21 billion and Orthopaedics net sales of $2.81 billion. Net earnings rose 13.9% to $0.74 billion, or $1.93 per share. For full-year 2026, the company expects organic net sales growth of 8.0% to 9.5% and adjusted net earnings per diluted share of $14.90 to $15.10. In the second quarter of 2025, consolidated net sales were $6.022 billion, with MedSurg and Neurotechnology net sales of $3.77 billion and Orthopaedics net sales of $2.25 billion.
Stryker Q1 revenue misses after cyberattack, Intuitive Surgical beats on da Vinci 5 demand
Stryker reported first-quarter revenue of $6.02 billion, missing the $6.33 billion consensus, while adjusted EPS of $2.60 fell short of the $2.98 estimate, after a March 11 cyberattack and $118 million in restructuring charges. Intuitive Surgical posted revenue of $2.77 billion, up 23%, with non-GAAP EPS of $2.50 topping the $2.11 consensus, driven by a roughly 16% rise in worldwide da Vinci procedures and 232 da Vinci 5 placements out of 431 total systems. Stryker's orthopaedic franchise showed resilience with 4.7% knee growth and 3.7% hip growth, while its vascular arm, boosted by the Inari deal, jumped 27.5%, and free cash flow surged 227% to $415 million. Intuitive guided da Vinci procedure growth of 13.5% to 15.5%, a step down from 18% in 2025, and faces a tariff hit of roughly 1% of revenue. Stryker trades at about 22 times forward earnings versus Intuitive's premium 39 times, and Stryker maintained full-year organic growth guidance of 8% to 9.5%.
Stryker Corporation highlighted for durable demand and dividend growth
A bullish thesis on Stryker Corporation emphasizes its entrenched position in healthcare, strong brand loyalty, and recurring procedure-driven demand. The medical technology company reported first-quarter 2026 net sales of $6.0 billion, up 2.6% year over year, with organic sales growth of 2.4% and adjusted earnings per share of $2.60. Management maintained full-year guidance of 8.5% organic sales growth and adjusted earnings per share of $14.90 to $15.10 despite a late-quarter cyber incident. Stryker pays an annual dividend of $3.52 per share, yielding 1.17% with a 40.74% payout ratio, and has increased its dividend for 16 consecutive years. The thesis points to the company's diversified portfolio across orthopedics, surgical equipment, and neurotechnology as a foundation for long-term earnings and cash flow compounding.
Stryker to trade ex-dividend June 30 for $0.88 quarterly payout
Stryker Corp will trade ex-dividend on June 30, 2026, for its quarterly dividend of $0.88 per share, payable on July 31, 2026. The dividend represents approximately 0.27% of the recent stock price of $331.79, with an annualized yield of about 1.06%. Stryker shares were down about 0.3% on Monday, trading at $330.49, within a 52-week range of $281 to $404.87.
SYK · Capital · Neutral News reports ex-dividend date and dividend amount, which is a capital event but does not change company value; stock price adjusts down by dividend amount.
Stryker Corporation announced the launch of TPX HD, a small bone power tool designed for demanding orthopaedic procedures including total joint revisions, minimally invasive surgery, and oral maxillofacial procedures. Mike Carlin, president of Stryker's Ortho Tech division, said revision surgeries are among the most demanding procedures, particularly when cutting metal, and that TPX HD was built for situations where visibility is limited, precision matters, and surgeons need a tool they can trust to perform. The device features a tapered attachment to improve visibility in confined spaces, a housing that helps reduce motor heat exposure at high operating speeds, and a shorter handpiece with an improved grip for better ergonomics. Stryker stated that TPX HD delivers up to 296% more torque and operates up to 40% faster than its TPX Micro Drill at high speed, and provides customizable controls through its CORE 2 Console and multiple specialized attachments.
SYK · Technology · Positive Stryker launches TPX HD, a new small bone power tool with improved torque, speed, and ergonomics for demanding orthopaedic procedures.
Leerink Lowers Stryker Price Target to $407, Maintains Outperform Rating
Leerink lowered its price target for Stryker to $407 from $410 while maintaining an Outperform rating, citing an attractive risk-reward despite a first-quarter revenue miss. The company reported earnings per share of $2.60 versus an estimate of $2.98, with revenue of $6 billion falling short of the expected $6.34 billion. Stryker reiterated its 2026 projection, and management expects a significant portion of the revenue deficit from a cyberattack to be recovered in the second half of the year. Leerink reduced its fiscal 2027 and 2028 earnings per share estimates by about 1% but still views Stryker as one of the better-positioned names in large-cap medical technology.
Stryker Introduces Pangea Plating System in Europe, BofA Cuts Target to $380
Stryker Corp. introduced its Pangea Plating System to the European market on May 26, a hardware platform designed to treat various bone fracture patterns. The initial clinical case in Europe was handled by Prof. Alex Trompeter and his team at St. George's University Hospital in London. The system combines plates with dedicated instruments to provide versatile fixation options for upper and lower limb fractures. On June 12, Bank of America Securities lowered its price target on Stryker from $450 to $380 while maintaining a Buy rating, citing lower utilization levels and a conservative stance on 2027 forecasts for medical technology companies.
Healthcare Equipment and Supplies Stocks Post Mixed Q1 Results
Healthcare equipment and supplies stocks reported mixed first-quarter results, with the 37 companies tracked collectively beating revenue estimates by 2.3% but issuing next-quarter guidance 1.3% below expectations. Lantheus posted revenues of $377.3 million, up 1.2% year on year and exceeding estimates by 6.4%, though its full-year revenue guidance missed. STAAR Surgical delivered the strongest performance, with revenues surging 120% to $93.52 million and beating estimates by 20.8%, while Stryker was the weakest, reporting $6.02 billion in revenue that fell 5% short of expectations. Abbott Laboratories reported $11.16 billion in revenue, up 7.8% and beating estimates by 1.3%, and Integra LifeSciences posted $391.9 million, up 2.4% and exceeding estimates by 2.6%. On average, share prices across the group have declined 1.4% since the latest earnings results.
Stryker's Free Cash Flow Hits 137% of Net Income, Revealing Overlooked Resilience
Stryker's free cash flow over the last twelve months reached approximately 137% of its reported net income, signaling a cash-generation strength that the market may be overlooking amid a recent cyberattack and a 17.6% stock decline over the past year. The company reiterated full-year organic net sales growth guidance of 8% to 9.5%, despite first-quarter organic sales growth of just 2.4%, and its robust cash conversion provides the financial fuel to absorb incident costs and fund operational recovery without sacrificing long-term investments. This cash-flow fortress supports the credibility of management's rebound target and suggests the underlying business is healthier than the recent disruption implies.
SYK · Capital · Positive Strong free cash flow at 137% of net income signals financial resilience and supports management's rebound target, despite recent cyberattack and stock decline.
GE HealthCare Q1 revenue beats but full-year EPS guidance disappoints
GE HealthCare reported first-quarter revenues of $5.13 billion, up 7.4% year on year and exceeding analyst expectations by 2.1%, but the company significantly missed full-year EPS guidance and quarterly EPS estimates. The stock fell 11.1% since the report and now trades at $60.91. Among the 37 healthcare equipment and supplies stocks tracked, aggregate revenues beat consensus by 2.3% while next-quarter revenue guidance came in 1.3% below estimates. STAAR Surgical posted the strongest performance with revenues of $93.52 million, up 120% year on year and beating estimates by 20.8%, while Stryker was the weakest with revenues of $6.02 billion, up 2.6% but missing expectations by 5%.
BofA Cuts Stryker Price Target to $380, Maintains Buy Rating
BofA lowered its price target on Stryker Corporation to $380 from $450 while maintaining a Buy rating on the shares. The firm cited a softer healthcare utilization environment and adopted a more conservative outlook for 2027 across the medical technology sector. The analyst also incorporated assumptions of increased inflationary pressures and reduced margin expansion potential for medtech companies, leading to lower earnings estimates for larger-cap names with exposure to procedure volumes and cost inflation.
Jim Cramer Says Stryker and Its Orthopedic Peers Are Facing a Real Tough Run
Jim Cramer said on Mad Money that Stryker and its orthopedic peers are facing a real tough run. He noted he had expected consolidation in the group, with Stryker as the consolidator, and mentioned Johnson & Johnson is spinning off its orthopedics, but that has not materialized. Cramer said he likes Stryker but not as much as Intuitive Surgical, which he prefers. Since his comments aired on May 23, 2025, Stryker's stock has declined around 17%.
USA
